Feb 6 (Reuters) - Labcorp ( LH ) forecast 2025 revenue

above Wall Street estimates after reporting fourth-quarter

results beat on Thursday, banking on robust demand for its

diagnostic tests.

Demand for diagnostic tests has grown in recent quarters as

more people, especially older adults, caught up on procedures

after the pandemic.

The company expects annual revenue in the range of $13.88

billion to $14.05 billion, above analysts' average estimate of

$13.8 billion, according to data compiled by LSEG.

It expects its 2025 adjusted profit to be between $15.60 and

$16.40 per share, with its midpoint in line with estimates of

$16.02 per share.

Peer Quest Diagnostics ( DGX ) also beat Wall Street

estimates for fourth-quarter profit and revenue last week,

helped by a robust appetite for its diagnostic tests.

The company's fourth-quarter sales rose 9.8% to $3.33

billion, beating analysts' average estimate of $3.31 billion.

Sales in its smaller biopharma laboratory services unit,

which offers contract research facilities for biopharmaceutical

companies, rose 10.4% to $767 million.

On an adjusted basis, Labcorp ( LH ) posted a profit of $3.45 per

share in the quarter ended December 31, above estimates of

$3.39.